Menu
Recruiting NCT06011980

Life-2023-02 Esophagogastric Variceal Bleeding

No phase Interventional Acute Esophageal Variceal Hemorrhage

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Growth Inhibitor.
Who it may be relevant to
Registry conditions: Acute Esophageal Variceal Hemorrhage. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Life-2023-02 Study on the Efficacy of Growth Inhibitors After Endoscopic Treatment of Acute Esophagogastric Variceal Bleeding

Overview

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Detailed description

Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.

Interventions

  • Drug Growth Inhibitor
    growth inhibitors for 250-500μg/h, ivgtt. for 5 days

Primary outcome measures

  • rebleeding rate after the endoscopic treatment in Group A at 1 month [Time frame: 1 month after the endoscopic treatment]
  • rebleeding rate after the endoscopic treatment in Group A at 3 months [Time frame: 3 months after the endoscopic treatment]
  • rebleeding rate after the endoscopic treatment in Group A at 6 months [Time frame: 6 months after the endoscopic treatment]
  • rebleeding rate after the endoscopic treatment in Group B at 1 month [Time frame: 1 month after the endoscopic treatment]
  • rebleeding rate after the endoscopic treatment in Group B at 3 months [Time frame: 3 months after the endoscopic treatment]
  • rebleeding rate after the endoscopic treatment in Group B at 6 months [Time frame: 6 months after the endoscopic treatment]

Eligibility criteria

Inclusion criteria

  • acute esophagogastric bleeding with hepatic cirhosis;
  • stable status (no active bleeding)

Exclusion criteria

  • endoscopic test limitation;
  • previous acute esophagogastric bleeding treatment history;
  • ICU;
  • pregnant;
  • Immunity disabled;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University — Hanzhou

Identifiers

NCT: NCT06011980 · 2023-0407

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗